Teva Pharmaceutical Industries Limited
TEVJF
$16.11
$2.3116.74%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.82% | 4.40% | 9.81% | 8.47% | 7.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.82% | 4.40% | 9.81% | 8.47% | 7.22% |
| Cost of Revenue | 3.38% | 3.40% | 1.68% | 0.34% | 0.74% |
| Gross Profit | 4.29% | 5.48% | 19.43% | 18.25% | 14.94% |
| SG&A Expenses | 5.42% | 5.80% | 6.35% | 4.69% | 3.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 183.33% | -175.00% | -101.64% | -83.58% | -112.12% |
| Total Operating Expenses | 4.19% | 3.99% | 2.64% | 2.11% | 1.59% |
| Operating Income | 2.42% | 6.07% | 45.27% | 40.63% | 35.74% |
| Income Before Tax | 36.78% | -106.43% | 77.27% | 93.58% | 66.65% |
| Income Tax Expenses | 2,153.85% | 11,350.00% | 574.51% | 174.66% | 94.12% |
| Earnings from Continuing Operations | -68.80% | -218.02% | 49.90% | 69.35% | 56.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -88.78% | 471.43% | 180.43% | 206.19% | 240.45% |
| Net Income | -168.48% | -192.68% | 58.96% | 80.72% | 71.99% |
| EBIT | 2.42% | 6.07% | 45.27% | 40.63% | 35.74% |
| EBITDA | -0.20% | 2.28% | 27.27% | 23.09% | 18.98% |
| EPS Basic | -165.52% | -188.79% | 59.79% | 81.22% | 72.20% |
| Normalized Basic EPS | -10.17% | 29.93% | 86.62% | 81.07% | 67.79% |
| EPS Diluted | -161.53% | -181.76% | 59.09% | 80.58% | 71.46% |
| Normalized Diluted EPS | -9.83% | 31.09% | 86.42% | 80.19% | 66.91% |
| Average Basic Shares Outstanding | 1.16% | 1.01% | 0.96% | 0.92% | 0.85% |
| Average Diluted Shares Outstanding | 0.95% | 0.33% | 1.00% | 1.41% | 1.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |